 |
| |
Arpida Ltd. is a Switzerland-based biopharmaceutical company engaged in the research, development and marketing of medical drugs, with a focus on the discovery and development of drugs that seek to overcome microbial resistance. The Company uses its fully integrated technology platform to aid the development of drug candidates that counter bacterial resistance to existing antibiotics. Arpida's main product is the intravenous broad-spectrum antibiotic, iclaprim, which targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). Arpida's other main drug is AR-709, an antibiotic that targets respiratory tract infections. The Company also has an antifungal therapy (TLT) which is in Phase III clinical trials in Europe, targeting onychomycosis. The Company's wholly owned subsidiaries are TLT Medical Ltd., Arpida Inc., United States, Arpida UK Ltd, United Kingdom, and Arpida A/S (formerly Combio A/S), Denmark.
Arpida Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary
Arpida Ltd. (Arpida) is a Switzerland biopharmaceutical company that focuses on the discovery, development and commercialisation of novel products for the treatment of microbial infections. Arpida has a fully-integrated platform to discover and develop drug candidates for bacterial resistance to existing antibiotics and thus meet a growing medical need in both the hospital and community setting. The Company's wholly owned subsidiaries are TLT Medical Ltd., Arpida Inc., United States, Arpida UK Ltd, United Kingdom, and Arpida A/S, Denmark
The Arpida Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile is an essential source for company data and information. The profile examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy as well as highlighting the company's major recent financial deals.
Scope
- Provides key company information for business intelligence needs
- Gives information on the company's major recent financial deals including Mergers and Acquisitions, asset transactions, PE/VC deals, equity offerings, debt offerings and partnerships.
- Data is supplemented with details on the company's history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.
Reasons to buy
- A quick "one-stop-shop" to understand the company.
- Support sales activities by understanding your customers' businesses.
- Qualify prospective partners and suppliers.
- Understand and respond to your competitors' business structure, strategy and prospects through.
- Understanding the key deals which have shaped the company.
Arpida Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile: http://www.companiesandmarkets.com/r.ashx?id=X9D5F7C68166545
|
—
